ImmunityBio, Inc.
IBRX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $113M | $14.7M | +669% |
| Operating income | −$256M | −$344M | +25.6% |
| Net income | −$351M | −$414M | +15.0% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $48.8M | $32.1M | +52.0% |
| Operating income | −$78.0M | −$55.6M | −40.3% |
| Net income | −$185M | −$67.3M | −174% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was ImmunityBio's revenue in FY2025?
- $113M in FY2025 (Fiscal year ended Dec 31, 2025), +669% vs $14.7M a year earlier, per its 10-K filed Feb 2026.
- Was ImmunityBio profitable in FY2025?
- No: net income was −$351M and operating income −$256M in FY2025.
- What was ImmunityBio's revenue in Q3 2026?
- $48.8M (+52.0% vs a year earlier), per its Form 10-Q filed Nov 9, 2026.